Chiesi Global Rare Diseases Presents Long-Term Results from Phase 3 BALANCE and BRIGHT Studies in Fabry Disease at the 19th Annual WORLDSymposium™ Research Meeting

BOSTONFeb. 24, 2023 /PRNewswire/ — Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people living with rare diseases, today announced the oral presentation of long-term results from the Phase 3 BALANCE and BRIGHT studies that evaluated PRX-102 (pegunigalsidase alfa), an investigational, plant cell culture-expressed, and chemically-modified, stabilized version of the recombinant α Galactosidase A enzyme for the proposed treatment of Fabry disease, at the 19th Annual WORLDSymposium™ Research Meeting that is being held February 22–26, 2023 in Orlando.

Michael Bond

Michael Bond

Leave a Reply

Your email address will not be published. Required fields are marked *